Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer
Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer
复制标题
DOI：
10.1007/s00345-003-0339-y
复制
发表时间：
2003-08-01
影响因子：
3.4
通讯作者：
Giannopoulos, A
中科院分区：
文献类型：
--
作者：
Constantinides, C;Lazaris, AC;Giannopoulos, A
胃泌素释放肽（GRP）是一种神经肽，已被认为在一些恶性肿瘤的发展中发挥作用。我们的目的是：(1)确定GRP在癌性前列腺中的表达，(2)将其表达与各种病理参数和患者的临床结果联系起来。采用标准免疫组织化学方法，我们评估了30例前列腺腺癌活检和根治性前列腺切除术标本中GRP的表达。18例根治性前列腺切除术标本（60%）和15例活检标本（50%）表达GRP。GRP阳性表达与复发（P=0.029）与肿瘤分期（即pT3、pT4）之间存在相关性（P=0.049）。在各自的活检中，GRP免疫状态与随后根治性前列腺切除术标本中观察到的相似。GRP免疫表达可能作为诊断和预后指标具有一定价值。病理标本显示GRP免疫阳性的患者应密切监测，因为他们似乎有更高的疾病进展和复发风险。
Gastrin releasing peptide (GRP) is a neuropeptide that has been suggested to play a role in the development of some malignancies. Our aim was: (1) to identify the expression of GRP in cancerous prostate glands, and (2) to correlate its expression to various pathological parameters and to the patient's clinical outcome. Using standard immunohistochemistry, we evaluated GRP expression in both biopsy and radical prostatectomy specimens from 30 patients with prostatic adenocarcinomas. GRP was expressed in 18 radical prostatectomy specimens (60%) and in 15 biopsies (50%). There was an association between positive immunoexpression of GRP, relapse (P=0.029) and advanced tumor stages (i.e. pT3, pT4) (P=0.049). In the respective biopsies, GRP immunostatus was similar to that observed in the subsequent radical prostatectomy specimens. GRP immunoexpression may be of some value as a diagnostic and prognostic marker. Patients whose pathology specimens demonstrate GRP immunopositivity should be closely monitored, since they appear to be at higher risk of disease progression and relapse.